Skip to main content
. 2019 Jul 1;5(7):FSO400. doi: 10.2144/fsoa-2019-0023

Table 5. . Follow-up amantadine test in the outlier group at Dhaka (Bangladesh site).

Subject ID Initial Follow-up 1 Follow-up 2
  2 h [AA] (ng/ml) 4 h [AA] (ng/ml) 6 h [AA] (ng/ml) 2 h [AA] (ng/ml) 4 h [AA] (ng/ml) 6 h [AA] (ng/ml) 2 h [AA] (ng/ml) 4 h [AA] (ng/ml) 6 h [AA] (ng/ml)
H03 11.9 165 156 21.0 30.3 41.4 11.4 113 30.9
H07 11.0 29.1 66.4 28.4 60.2 64.7 1.7 33.4 19.5
H11 3.0 185 45.1 7.1 36.3 77.2 1.5 45.2 67.3
H12 31.4 132 91.3 92.6 81.5 46.5 46.1 120 54.9
H17 9.8 60.8 27.3 39.4 71.2 42.3 6.7 25.0 48.3
H18 22.8 28.2 25.1 17.5 74.9 103 5.9 19.7 9.3
H26 14.9 24.0 8.0 6.8 46.9 21.5 1.8 14.3 26.4

Urinary AA concentrations were determined at 2, 4 and 6 h postamantadine ingestion at first follow-up (6 month) and at second follow-up (9-month) after the initial amantadine test.

AA: Acetylamantadine.